Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

King Gets Inventories Under Control; Next Step Is Boosting Brand Sales

Executive Summary

King Pharmaceuticals has dramatically reduced wholesale inventory levels and associated product return rates this year, the company said during its Nov. 9 third quarter earnings call

You may also be interested in...



King’s Best Price Settlement Covers Entire Product Portfolio

King's settlement of charges that it failed to properly calculate Medicaid best price rebates is far larger than most such settlements because it includes the company's entire portfolio

King Says It Can Grow On Its Own Following Collapse Of Mylan Merger Plans

King will not pursue a new merger partner following the collapse of its proposed agreement to be acquired by Mylan

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046558

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel